The therapeutic use of cannabis faces unique challenges that transcend pure science. From questionable international classifications to administrative interference, we examine the path toward evidence-based medicine for cannabinoids.
In brief
- Cannabinoid research faces historical and bureaucratic barriers that hinder access to validated treatments.
- International bodies like the INCB have excluded cannabis without rigorous scientific justification, stalling clinical study.
- The distinction between a drug and a medicine is artificial; the interference of anti-drug agencies in scientific matters compromises medical objectivity.
- The development of synthetic cannabinoids by the pharmaceutical industry often ignores the potential of the original, unpatentable plant.
Science under siege: a complex landscape
The development of new drugs for human treatment follows standardized protocols that have allowed for significant advances in recent decades. The process begins with basic research, computational simulations, and preclinical studies in cell cultures or animal models. These stages allow for the identification of promising molecules before subjecting them to human testing.
Once selected, these substances go through strict safety phases with healthy volunteers to evaluate their physiological behavior. If the results are satisfactory, the drug moves on to controlled clinical trials, where its efficacy is compared against placebos or other treatments in real patient populations. Only after demonstrating utility and safety does a medication obtain commercial authorization and indication for specific pathologies.
This scientific rigor clearly distinguishes between what works and what does not. However, cannabis presents a particularity: its therapeutic use is not only a subject of scientific debate but also political and social. While conventional drugs like antibiotics or antihypertensives enjoy medical consensus, cannabinoids are subjected to moral judgments that transcend clinical evidence.
History and prejudice: the origin of the stigma
The roots of this controversy date back to the beginning of the 20th century. In the United States and subsequently in much of the world, cannabis was prohibited based on a mixture of moral, social, and economic factors, but without solid health or scientific foundations.
None of the causes that led to the illegality of this substance focused on its impact on public health. Despite this, international bodies like the International Narcotics Control Board (INCB) have kept cannabis on restrictive lists since 1961, classifying it alongside substances with no therapeutic use and high toxicity. This categorization has acted as a brake on scientific research, as classifying a plant as “bad” a priori discourages its clinical study.
It is important to highlight that cannabis has been used for medicinal purposes for seven millennia by various cultures around the world. Despite this historical and ethnobotanical legacy, moral prejudices disguised as science systematically excluded it from modern pharmacological research.
The endogenous system: a scientific revolution
In the mid-70s, Israeli scientists discovered that the human body possesses its own regulatory system, the Endocannabinoid System. This mechanism uses natural molecules to control specific functions in the nervous and immune systems, acting on receptors similar to those of plant-based cannabinoids.
This finding transformed pharmacology and opened new therapeutic avenues. However, research has been hindered by multiple factors: complex bureaucratic procedures, burdensome administrative permits, and restrictive security conditions that discourage enthusiastic researchers.
Furthermore, drug development is expensive and slow. The pharmaceutical industry funds most new products but shows little interest in studying unpatentable plants like hemp, as they cannot obtain direct economic profits from them. Therefore, many companies focus on synthetic cannabinoids, ignoring the therapeutic potential of the natural plant.
Administrative interference and distortion of discourse
A critical factor hindering a rational approach is the interference of anti-drug authorities in scientific matters. These entities often exceed their legal competencies to enter the medical field, using ideological arguments instead of clinical evidence.
In public statements, some officials have categorically claimed that cannabis causes health damage without nuance or distinction between recreational and therapeutic use. It has been erroneously suggested that psychologically improving a terminally ill patient through cannabis use does not constitute a valid medical intervention to extend life.
Prevention organizations have warned about the “risk of confusion” generated by information on therapeutic dispensing, using terms like “trivialization” or “disorientation.” These positions suggest that any medical use must be purely synthetic and avoid traditional forms of administration like smoking, which contradicts historical practices and real clinical needs.
The artificiality of the drug-medicine distinction
It is crucial to understand that the dividing line between a medicine and a drug is fundamentally artificial. The difference lies in the context of use: a medication is prescribed to treat diseases, while an unregulated psychoactive substance is usually self-administered without medical supervision.
The existence of therapeutic properties in cannabis represents a direct challenge to prohibitionist logic. Recognizing its medical utility contradicts the idea that certain substances are inherently harmful and must be prohibited to protect an abstract “public health.”
Toward evidence-based medicine
The manipulation of discourse by anti-drug lobbies and the self-serving use by the pro-cannabis sector further complicate the landscape. It is necessary to maintain a critical approach, distinguishing between scientific facts, unverified hypotheses, and ideological opinions.
The future of cannabinoid research depends on overcoming these historical and bureaucratic barriers. Only through interdisciplinary collaboration that integrates science, ethics, and public health can we move toward more effective and safer treatments for patients who need them.
Editorial closing
At Psiconáutica.org, we understand the importance of addressing complex topics with scientific rigor and human sensitivity. Therapeutic cannabis is not just a pharmacological issue; it is a reflection of how society faces knowledge in the face of deep-seated prejudices.
Fostering education, promoting harm reduction, and supporting independent research are essential steps to building a future where medicine can fully benefit from the therapeutic potential of cannabinoids. Critical consciousness and open dialogue are fundamental tools on this path toward comprehensive health.
